Skip to main content
Journal cover image

Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.

Publication ,  Journal Article
Yi, H; Sun, T; Armstrong, D; Borneman, S; Yang, C; Austin, S; Kishnani, PS; Sun, B
Published in: J Mol Med (Berl)
May 2017

UNLABELLED: Pompe disease is characterized by accumulation of both lysosomal and cytoplasmic glycogen primarily in skeletal and cardiac muscles. Mannose-6-phosphate receptor-mediated enzyme replacement therapy (ERT) with recombinant human acid α-glucosidase (rhGAA) targets the enzyme to lysosomes and thus is unable to digest cytoplasmic glycogen. Studies have shown that anti-DNA antibody 3E10 penetrates living cells and delivers "cargo" proteins to the cytosol or nucleus via equilibrative nucleoside transporter ENT2. We speculate that 3E10-mediated ERT with GAA will target both lysosomal and cytoplasmic glycogen in Pompe disease. A fusion protein (FabGAA) containing a humanized Fab fragment derived from the murine 3E10 antibody and the 110 kDa human GAA precursor was constructed and produced in CHO cells. Immunostaining with an anti-Fab antibody revealed that the Fab signals did not co-localize with the lysosomal marker LAMP2 in cultured L6 myoblasts or Pompe patient fibroblasts after incubation with FabGAA. Western blot with an anti-GAA antibody showed presence of the 150 kDa full-length FabGAA in the cell lysates, in addition to the 95- and 76 kDa processed forms of GAA that were also seen in the rhGAA-treated cells. Blocking of mannose-6-phosphate receptor with mannose-6-phosphate markedly reduced the 95- and the 76 kDa forms but not the 150 kDa form. In GAA-KO mice, FabGAA achieved similar treatment efficacy as rhGAA at an equal molar dose in reducing tissue glycogen contents. Our data suggest that FabGAA retains the ability of rhGAA to treat lysosomal glycogen accumulation and has the beneficial potential over rhGAA to reduce cytoplasmic glycogen storage in Pompe disease. KEY MESSAGES: FabGAA can be delivered to both the cytoplasm and lysosomes in cultured cells. FabGAA equally reduced lysosomal glycogen accumulation as rhGAA in GAA-KO mice. FabGAA has the beneficial potential over rhGAA to clear cytoplasmic glycogen. This study suggests a novel antibody-enzyme fusion protein therapy for Pompe disease.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Mol Med (Berl)

DOI

EISSN

1432-1440

Publication Date

May 2017

Volume

95

Issue

5

Start / End Page

513 / 521

Location

Germany

Related Subject Headings

  • alpha-Glucosidases
  • Mice, Knockout
  • Mice
  • Lysosomes
  • Immunology
  • Humans
  • Glycogen Storage Disease Type II
  • Glycogen
  • Enzyme Replacement Therapy
  • Cytoplasm
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Yi, H., Sun, T., Armstrong, D., Borneman, S., Yang, C., Austin, S., … Sun, B. (2017). Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease. J Mol Med (Berl), 95(5), 513–521. https://doi.org/10.1007/s00109-017-1505-9
Yi, Haiqing, Tao Sun, Dustin Armstrong, Scott Borneman, Chunyu Yang, Stephanie Austin, Priya S. Kishnani, and Baodong Sun. “Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.J Mol Med (Berl) 95, no. 5 (May 2017): 513–21. https://doi.org/10.1007/s00109-017-1505-9.
Yi H, Sun T, Armstrong D, Borneman S, Yang C, Austin S, et al. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease. J Mol Med (Berl). 2017 May;95(5):513–21.
Yi, Haiqing, et al. “Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.J Mol Med (Berl), vol. 95, no. 5, May 2017, pp. 513–21. Pubmed, doi:10.1007/s00109-017-1505-9.
Yi H, Sun T, Armstrong D, Borneman S, Yang C, Austin S, Kishnani PS, Sun B. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease. J Mol Med (Berl). 2017 May;95(5):513–521.
Journal cover image

Published In

J Mol Med (Berl)

DOI

EISSN

1432-1440

Publication Date

May 2017

Volume

95

Issue

5

Start / End Page

513 / 521

Location

Germany

Related Subject Headings

  • alpha-Glucosidases
  • Mice, Knockout
  • Mice
  • Lysosomes
  • Immunology
  • Humans
  • Glycogen Storage Disease Type II
  • Glycogen
  • Enzyme Replacement Therapy
  • Cytoplasm